. Author manuscript; available in PMC: 2023 Oct 18.

Published in final edited form as: Lancet Infect Dis. 2016 Feb 20;16(6):674–684. doi: 10.1016/S1473-3099(15)00479-X

Table 1:

Baseline characteristics of participants overall and by primaquine dose group

	Overall (n=81)	Control group (0 mg/kg; n=16)	0·0625 mg/kg group (n=16)	0·125 mg/kg group (n=17)	0·25 mg/kg group (n=15)	0·5 mg/kg group (n=17)
Age (years)	12 (7–25)	22 (7–30)	10 (8–11)	22 (7–32)	10 (7–16)	18 (8–30)
Haemoglobin (g/L)	124 (112–138)	130 (110–139)	120 (108–129)	135 (111–144)	119 (112–132)	122 (113–142)
Gametocyte density by microscopy (per μL)	64 (32–720)	64 (32–144)	96 (48–576)	80 (32–320)	144 (48–720)	48 (32–192)
Asexual parasite prevalence by microscopy	54 (67%)	8 (50%)	11 (69%)	14 (82%)	8 (53%)	13 (77%)
Asexual parasite density by microscopy (per μL)^*	376 (64–2128)	176 (40–3840)	1088 (144–2832)	216 (48–1264)	1656 (432–9808)	144 (32–1792)
Symptomatic malaria^†	6 (7%)	0	3 (19%)	1 (6%)	0	2 (12%)

Data are median (IQR) or n (%). * Median parasite densities were calculated for parasite-positive individuals only. † Temperature ≥37·5°C and parasitaemic.